Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca ( (AZN) ) has shared an update.
On August 13, 2025, The Capital Group Companies, Inc. increased its voting rights in AstraZeneca PLC to 5.009591%, crossing a significant threshold. This change, notified to AstraZeneca on August 14, 2025, reflects a strategic move by the investment management firm, potentially impacting AstraZeneca’s shareholder dynamics and market perception.
The most recent analyst rating on (AZN) stock is a Buy with a $91.70 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the AZN Stock Forecast page.
Spark’s Take on AZN Stock
According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.
AstraZeneca’s overall score is bolstered by strong financial performance and a positive earnings call, reflecting robust growth and a promising pipeline. While the valuation suggests potential overvaluation, technical indicators support a stable uptrend.
To see Spark’s full report on AZN stock, click here.
More about AstraZeneca
AstraZeneca PLC is a leading global biopharmaceutical company based in the United Kingdom, primarily focused on the discovery, development, and commercialization of prescription medicines. The company operates in various therapeutic areas, including oncology, cardiovascular, renal, and metabolism, as well as respiratory and immunology.
Average Trading Volume: 4,565,363
Technical Sentiment Signal: Strong Buy
Current Market Cap: $243.2B
For a thorough assessment of AZN stock, go to TipRanks’ Stock Analysis page.